SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-002816
Filing Date
2023-01-10
Accepted
2023-01-10 17:29:23
Documents
5
Period of Report
2023-02-02

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2233294-2_def14a.htm DEF 14A 147086
2 GRAPHIC lg_nrx-4clr.jpg GRAPHIC 57289
3 GRAPHIC px_nrxpharma01pg-bw.jpg GRAPHIC 809819
4 GRAPHIC px_nrxpharma02pg-bw.jpg GRAPHIC 543110
5 GRAPHIC sg_michaelkunz-bw.jpg GRAPHIC 6735
  Complete submission text file 0001104659-23-002816.txt   1827595
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38302 | Film No.: 23522005
SIC: 2834 Pharmaceutical Preparations